Citius Pharmaceuticals Inc. Common
CTXRCitius Pharmaceuticals Inc. (CTXR) is a specialty pharmaceutical company focused on developing and commercializing innovative products for the hospital, infusion, and existing retail markets. The company emphasizes therapies for unmet medical needs, often in areas such as wound care, infection control, and other critical healthcare sectors. Their pipeline includes products aimed at improving patient outcomes and addressing niche medical indications.
Company News
U.S. stock futures declined slightly on Christmas Eve despite a strong Q3 GDP report showing 4.3% annualized growth. Major indices ended higher on Tuesday, with communication services, IT, and energy stocks leading gains. Several stocks gained attention: UiPath jumped 7% after joining the S&P Midcap 400, Citius Pharmaceuticals rose 8.65% on bette...
Citius Oncology closed a registered direct offering and private placement, raising approximately $18 million to support the commercial launch of LYMPHIR and for general corporate purposes.
Citius Oncology raised $18 million through a registered direct offering and private placement to support the commercial launch of LYMPHIR, a novel cancer immunotherapy for cutaneous T-cell lymphoma, with H.C. Wainwright & Co. acting as the exclusive placement agent.
Citius Oncology closed a $9.0 million registered direct offering and private placement, issuing 5,142,858 shares of common stock and accompanying warrants at $1.75 per share, with warrants exercisable at $1.84 per share.
Citius Oncology has entered a securities purchase agreement to sell 5,142,858 shares of common stock at $1.75 per share, with concurrent warrants, expected to raise approximately $9.0 million.
